Eurofins Genomics
Driving Innovation With Next Generation Sequencing

Today’s highly complicated genomics requirements are beyond the scope of traditional DNA sequencing technologies. Next-Generation Sequencing (NSG), on the other hand, is rising to the occasion and offering ultra-high throughput, speed, and scalability. NSG technologies are used to determine the order of nucleotides in genomes or targeted regions of RNA and DNAs, empowering laboratories to perform various operations and systematic biological studies. A name that is synonymous with NSG and well known in Europe’s life sciences industry is Eurofins Genomics. Founded in 1990, the life science company is a part of Eurofins Scientific Group that operates across hundreds of laboratories in forty-eight countries.

Eurofins Genomics is a global provider of genomics services geared around the group’s core offering of NSG, genotyping, gene expression, custom DNA sequencing, and gene synthesis. The firm offers bespoke services tailored to the specified requirements of pharmaceuticals, agricultural and biotechnology firms, and life science research institutions. Driven by its passion for DNA sequencing, Eurofins Genomics forges strong bonds with its customers and ensures that they efficiently leverage the technology. Globally known for its innovative and customizable solutions, the company offers its clients a combination of knowledge and experience of its international network of companies in the field of genomics, forensics, environmental, and food sciences. This unique association underscores Eurofins Genomics’ commitment towards offering the best practice solutions and concepts to its clients.

Eurofins Genomics’ NSG services are available on various instruments, allowing it to combine its best technologies to generate optimal solutions for clients’ requisites. Considering that NSG is employed not only for deep sequencing but also for data analysis and project consulting, Eurofins Genomics comprehensively understands its clients’ requirements and designs projects that flawlessly fit their needs. The company’s genomic and transcriptome sequencing services for de novo as well as re-sequencing of genomes. Users can compare expression levels of various transcripts from different samples, identify novel RNAs or target molecules, and generate a complete portfolio for re-sequencing regions. In small regions, Eurofins Genomics’s NSG preferably amplifies it and generates a PCR product to facilitate the detection of genetic variations or execute metagenome analysis. Owing to this multiplexing capability, the solutions can analyze several samples simultaneously, drastically reducing the cost per sample. Researchers can selectively enrich a particular genome region from highly complex genomic DNA. Additionally, Eurofins Genomics’ sample preparation solutions complement its NSG technology, bringing together several aspects of genomics.

Whether a requirement is for sequencing, a standard genome, or a new species, Eurofins Genomics possesses the expertise to prepare reliable samples. Its applied genetics department is world-renowned for its DNA preparation capabilities, from food to forensic samples. Eurofins Genomics products are of the highest caliber and are developed under strict Quality Management (QM), and Quality Assurance (QA) protocols and are ISO, GLP, and GCP certified. In the past couple of years, NSG has progressed from research to clinical use. With several countries creating initiatives to promote its utilization, it is evident that next-gen sequencing will be driving development in the life sciences industry. The technology is already finding significant applications in the RNA sequencing of the SARS-CoV-2 virus and is assisting researchers in carrying out real-time phylogenetic studies. With its customer-centric approach, efficient, and systematic NSG solutions, Eurofins Genomics will remain at the forefront of this revolution and foster innovation in the sector.